PATENT COOPERATION TREATY

PCT

THIRD PARTY OBSERVATION

(PCT Administrative Instructions Part 8)

Applicant's or agent's file reference 0614-00107	
International application number PCT/IB2022/054049	International filing date (day/month/year) 02 May 2022 (02/05/2022)
Applicant UNIVERSITATSSPITAL BASEL	

Third party observation submitted by Taylor KURTZWEIL	Observation submitted on behalf of Porta Sophia Psychedelic Prior Art Library
Date of submission(day/month/year) 08 Jun 2023 (08/06/2023)	Language of observation English

Basis and contents of observation

1. The observation is made on the basis of the claims in the international application as filed.
2. The observation comprises:
   References to documents: 3
   Uploaded copies of documents: 2
3. Further explanations:
   Uploaded copies of documents: 0

Citation # 1(Periodical article) (# uploaded documents:1):

Author:	Title of article:	Title of Periodical:	Publication Date:
H.A. Abramson, A. Rolo	Lysergic acid diethylamide (LSD-25). 38. Comparison with action of methysergide and psilocybin on test subjects	Journal of Asthma Research	Sep 1965 (09/1965)

Issue Number of Periodical: Volume 3 Issue 1	Publisher of Periodical:	Place of publication:
Page range of article within periodical: 81-96	ISBN:	ISSN:
DOI:		

Most relevant passages or drawings: Page 95	Relevant to Claims: 1

Brief explanation of relevance:

From Page 95 “Although it was found that differences in the rates of action and in the duration of action were observed, the effects of the drugs, as measured by the questionnaire, were strikingly similar at their respective dosages just above the threshold level and at 2 to 3 times above these levels. One hundred and seventy mcg of methysergide and one hundred and thirty-five mcg of psilocybin are estimated to be equal to 1 mcg of LSD near the threshold level of dosage.” Relevant to WO2023012524 claim 1

Citation # 2(Periodical article) (# uploaded documents:1):

Author:	Title of article:	Title of Periodical:	Publication Date:
Juan Jose Fuentes et al.	Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials	Frontiers in Psychiatry	21 Jan 2020 (21/01/2020)

Issue Number of Periodical:	Publisher of Periodical:	Place of publication:
Volume 10		
Page range of article within periodical:	ISBN:	ISSN:

DOI:

Most relevant passages or drawings:	Relevant to Claims:
Abstract	2

Brief explanation of relevance:

From Abstract “Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction.” Relevant to WO2023012524 Claim 2

Citation # 3 (Patent/utility model) (# uploaded documents: 0):

Country code:	Publication number:	Document kind code:
WO	2021211358	A1

Patent Applicant/Patent Owner:	Title of invention:
UNIV BASEL	LSD DOSE IDENTIFICATION

Link to document:

Publication Date:	Filing Date:	Priority Date:
21 Oct 2021 (21/10/2021)		13 Apr 2020 (13/04/2020)

Source of Abstract:	Accession number:	Publication Date of Abstract:	Retrieval Date of Abstract:

Most relevant passages or drawings:	Relevant to Claims:
See explanation	See explanation

Brief explanation of relevance:

From Claim 37 “The method of claim 36, wherein the individual has a condition chosen from the group consisting of depression, anxiety, substance use disorder, addiction, personality disorder, eating disorder, post-traumatic stress disorder, obsessive compulsive disorder, pain disorders, migraine, cluster headache, and requiring palliative care.” Relevant to WO2023012524 Claim 2

From [00037] “Generally, the present invention provides for a method of dosing and treating patients with a psychedelic, by administering a psychedelic (such as LSD or a salt thereof) at a specific dose defined below such as a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, and producing maximum positive subjective acute effects that are known to be associated with more positive long-term outcomes and minimizing negative acute effects.” Relevant to WO2023012524 Claims 3, 4, 7, 8

From [00038] ““Positive acute effects” as used herein refers primarily to an increase in subjective rating of “good drug effect” and may also include ratings of “drug liking”, “well-being”, “oceanic boundlessness”, “experience of unity”, “spiritual experience”, “blissful state”, “insightfulness”, any “ mystical-type experience” and positively experienced “psychedelic effects”, and “aspects of ego-dissolution” if experienced without anxiety. Relevant to WO2023012524 Claim 3

From Claim 5 “The method of claim 1, wherein the psychedelic is chosen from the group consisting of LSD, psilocybin, mescaline, dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, analogs thereof, and

homologues thereof." Relevant to WO2023012524 Claim 3

From [00039] ""Negative acute effects" as used herein refers primarily to subjective ratings of "bad drug effect" and "anxiety" and "fear" and may additionally include increased ratings of "anxious ego-dissolution", or descriptions of acute paranoia or states of panic an anxiety as observed by others." Relevant to WO2023012524 Claim 4

From Claim 5 "The method of claim 1, wherein the psychedelic is chosen from the group consisting of LSD, psilocybin, mescaline, dimethyltryptamine (DMT), 2,5-dimethoxy-4-iodoamphetamine (DOI), 2,5-dimethoxy-4-bromoamphetamie (DOB), salts thereof, tartrates thereof, analogs thereof, and homologues thereof." Relevant to WO2023012524 Claims 5, 6, 8

From Claim 6 "The method of claim 1, wherein the dose is a microdose of 1 -20 mcg" Relevant to WO2023012524 Claim 5

From Claim 7 "The method of claim 1, wherein the dose is a minidose of 21 -29 mcg." Relevant to WO2023012524 Claim 5

From Claim 8 "The method of claim 1, wherein the dose is a psychedelic dose of greater than 30 mcg." Relevant to WO2023012524 Claim 5

From Claim 9 "The method of claim 1, wherein the dose is a good effect dose of 30-100 mcg." Relevant to WO2023012524 Claim 5

From Claim 10 "The method of claim 1, wherein the dose is an ego-dissolution dose of greater than 100 mcg" Relevant to WO2023012524 Claims 5, 6

From Claim 11 "The method of claim 1, wherein the dose is a cardiovascular safe dose of 50-200 mcg." Relevant to WO2023012524 Claim 5

From [00015] "The present invention provides for a method of defining therapeutic doses of a psychedelic in clinical trials, by administering a dose of a psychedelic to a healthy individual in a phase 1 study of a microdose, minidose, psychedelic dose, good effect dose, ego-dissolution dose, or cardiovascular safe dose, determining positive acute effects and negative acute effects in the individual, adjusting the dose to provide more positive acute effects than negative acute effects in the individual, and using the adjusted dose for a phase 2 or phase 3 study in patients." Relevant to WO2023012524 Claim 9

From [00058] "The individual can be healthy, and the method can be used to predict doses for unhealthy individuals." Relevant to WO2023012524 Claim 9

From [0058] "This method can be used to determine long term dosing and dose schedules." Relevant to WO2023012524 Claim 10